Evidence map›Paper›PMID 23718762›Full record

ArticleRetrovirology2013

A novel acute HIV infection staging system based on 4th generation immunoassay.

Jintanat Ananworanich, James L K Fletcher, Suteeraporn Pinyakorn, Frits van Griensven, Claire Vandergeeten, Alexandra Schuetz, Tippawan Pankam, Rapee Trichavaroj, Siriwat Akapirat, Nitiya Chomchey and 6 more

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Activation of CXCR3Journal of virology · 2025
    Article
  17. Review
  18. Article
  19. Article
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 3 countries.

Jintanat AnanworanichSEARCH, Pathumwan, Bangkok, Thailand. Jintanat.A@searchThailand.org
James L K Fletcher
Suteeraporn Pinyakorn
Frits van Griensven
Claire Vandergeeten
Alexandra Schuetz
Tippawan Pankam
Rapee Trichavaroj
Siriwat Akapirat
Nitiya Chomchey
Praphan Phanuphak
Nicolas Chomont
Nelson L Michael
Jerome H Kim
Mark de Souza
RV254/SEARCH 010 Study Group
Thai Red Cross Society · THArmed Forces Research Institute of Medical Science · THHIV Netherlands Australia Thailand Research Collaboration · THVaccine & Gene Therapy Institute of Florida · USChulalongkorn University · THSeat (Spain) · ES

Funding

Northern/Pacific Universities Global Health Research Training ConsortiumR25TW009345 · FIC · UNIVERSITY OF WASHINGTON · PI KOLARS, JOSEPH C., NERURKAR, VIVEK RAMCHANDRA · 2012 to 2016
$5.9M
FIC NIH HHS R25 TW009345
6 · The paper itself

Abstract

backgroundFourth generation (4thG) immunoassay (IA) is becoming the standard HIV screening method but was not available when the Fiebig acute HIV infection (AHI) staging system was proposed. Here we evaluated AHI staging based on a 4thG IA (4thG staging).

findingsScreening for AHI was performed in real-time by pooled nucleic acid testing (NAT, n=48,828 samples) and sequential enzyme immunoassay (EIA, n=3,939 samples) identifying 63 subjects with non-reactive 2nd generation EIA (Fiebig stages I (n=25), II (n=7), III (n=29), IV (n=2)). The majority of samples tested (n=53) were subtype CRF_01AE (77%). NAT+ subjects were re-staged into three 4thG stages: stage 1 (n=20; 4th gen EIA-, 3rd gen EIA-), stage 2 (n=12; 4th gen EIA+, 3rd gen EIA-), stage 3 (n=31; 4th gen EIA+, 3rd gen EIA+, Western blot-/indeterminate). 4thG staging distinguishes groups of AHI subjects by time since presumed HIV exposure, pattern of CD8+ T, B and natural killer cell absolute numbers, and HIV RNA and DNA levels. This staging system further stratified Fiebig I subjects: 18 subjects in 4thG stage 1 had lower HIV RNA and DNA levels than 7 subjects in 4thG stage 2.

conclusionsUsing 4th generation IA as part of AHI staging distinguishes groups of patients by time since exposure to HIV, lymphocyte numbers and HIV viral burden. It identifies two groups of Fiebig stage I subjects who display different levels of HIV RNA and DNA, which may have implication for HIV cure. 4th generation IA should be incorporated into AHI staging systems.

Indexed as

Severity of Illness IndexAdultB-LymphocytesCD8-Positive T-LymphocytesDNA, ViralFemaleHIV InfectionsHumansImmunoassayKiller Cells, NaturalMaleMass ScreeningRNA, ViralTime FactorsViral LoadDNA, ViralRNA, Viral

Identifiers

PMID23718762
PMCPMC3669623
OpenAlexW2137791900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.